BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25740979)

  • 1. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.
    Goodwin PJ; Parulekar WR; Gelmon KA; Shepherd LE; Ligibel JA; Hershman DL; Rastogi P; Mayer IA; Hobday TJ; Lemieux J; Thompson AM; Pritchard KI; Whelan TJ; Mukherjee SD; Chalchal HI; Oja CD; Tonkin KS; Bernstein V; Chen BE; Stambolic V
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25740979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial.
    Goodwin PJ; Dowling RJO; Ennis M; Chen BE; Parulekar WR; Shepherd LE; Burnell MJ; Vander Meer R; Molckovsky A; Gurjal A; Gelmon KA; Ligibel JA; Hershman DL; Mayer IA; Whelan TJ; Hobday TJ; Rastogi P; Rabaglio-Poretti M; Lemieux J; Thompson AM; Rea DW; Stambolic V
    NPJ Breast Cancer; 2021 Jun; 7(1):74. PubMed ID: 34103538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
    Glueck CJ; Fontaine RN; Wang P; Subbiah MT; Weber K; Illig E; Streicher P; Sieve-Smith L; Tracy TM; Lang JE; McCullough P
    Metabolism; 2001 Jul; 50(7):856-61. PubMed ID: 11436194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo.
    Goodwin PJ; Dowling RJO; Ennis M; Chen BE; Parulekar WR; Shepherd LE; Gelmon KA; Whelan TJ; Ligibel JA; Hershman DL; Mayer IA; Hobday TJ; Rastogi P; Rabaglio-Poretti M; Lemieux J; Thompson AM; Rea DW; Stambolic V
    JNCI Cancer Spectr; 2021 Oct; 5(5):. PubMed ID: 34485814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.
    Carrizo E; Fernández V; Connell L; Sandia I; Prieto D; Mogollón J; Valbuena D; Fernández I; de Baptista EA; Baptista T
    Schizophr Res; 2009 Aug; 113(1):19-26. PubMed ID: 19515536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
    Bonanni B; Puntoni M; Cazzaniga M; Pruneri G; Serrano D; Guerrieri-Gonzaga A; Gennari A; Trabacca MS; Galimberti V; Veronesi P; Johansson H; Aristarco V; Bassi F; Luini A; Lazzeroni M; Varricchio C; Viale G; Bruzzi P; Decensi A
    J Clin Oncol; 2012 Jul; 30(21):2593-600. PubMed ID: 22564993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32.
    Pimentel I; Chen BE; Lohmann AE; Ennis M; Ligibel J; Shepherd L; Hershman DL; Whelan T; Stambolic V; Mayer I; Hobday T; Lemieux J; Thompson A; Rastogi P; Gelmon K; Rea D; Rabaglio M; Ellard S; Mates M; Bedard P; Pitre L; Vandenberg T; Dowling RJO; Parulekar W; Goodwin PJ
    J Natl Cancer Inst; 2021 Feb; 113(2):192-198. PubMed ID: 33527137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.
    Goodwin PJ; Ennis M; Pritchard KI; Trudeau ME; Koo J; Taylor SK; Hood N
    J Clin Oncol; 2012 Jan; 30(2):164-71. PubMed ID: 22162568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome.
    Bulcão C; Ribeiro-Filho FF; Sañudo A; Roberta Ferreira SG
    Am J Cardiovasc Drugs; 2007; 7(3):219-24. PubMed ID: 17610348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin use, adipokine profiles and breast cancer prognosis.
    Wintrob ZA; Hammel JP; Khoury T; Nimako GK; Fu HW; Fayazi ZS; Gaile DP; Forrest A; Ceacareanu AC
    Cytokine; 2017 Jan; 89():45-61. PubMed ID: 27914795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.
    Martinez JA; Chalasani P; Thomson CA; Roe D; Altbach M; Galons JP; Stopeck A; Thompson PA; Villa-Guillen DE; Chow HH
    BMC Cancer; 2016 Jul; 16():500. PubMed ID: 27430256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity?
    Bulcão C; Giuffrida FM; Ribeiro-Filho FF; Ferreira SR
    Braz J Med Biol Res; 2007 Feb; 40(2):229-35. PubMed ID: 17273659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men.
    Fruehwald-Schultes B; Oltmanns KM; Toschek B; Sopke S; Kern W; Born J; Fehm HL; Peters A
    Metabolism; 2002 Apr; 51(4):531-6. PubMed ID: 11912566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome.
    Akbar DH
    Endocrine; 2003 Apr; 20(3):215-8. PubMed ID: 12721499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The benefits of adding metformin to tamoxifen to protect the endometrium-A randomized placebo-controlled trial.
    Davis SR; Robinson PJ; Jane F; White S; Brown KA; Piessens S; Edwards A; McNeilage J; Woinarski J; Chipman M; Bell RJ
    Clin Endocrinol (Oxf); 2018 Nov; 89(5):605-612. PubMed ID: 30107043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
    Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S
    Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
    Baptista T; Sandia I; Lacruz A; Rangel N; de Mendoza S; Beaulieu S; Contreras Q; Galeazzi T; Vargas D
    Int Clin Psychopharmacol; 2007 Mar; 22(2):69-76. PubMed ID: 17293706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
    Moghetti P; Castello R; Negri C; Tosi F; Perrone F; Caputo M; Zanolin E; Muggeo M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):139-46. PubMed ID: 10634377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.